These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30585844)

  • 21. Effects of hypokalemia and hypomagnesemia on zidovudine (AZT) and didanosine (ddI) nephrotoxicity in rats.
    Seguro AC; de Araujo M; Seguro FS; Rienzo M; Magaldi AJ; Campos SB
    Clin Nephrol; 2003 Apr; 59(4):267-72. PubMed ID: 12708566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV.
    Bogorodskaya M; Fitch KV; Lu M; Torriani M; Zanni MV; Looby SE; Iyengar S; Triant VA; Grinspoon SK; Srinivasa S; Lo J
    Obesity (Silver Spring); 2020 Apr; 28(4):749-755. PubMed ID: 32086864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.
    McGee KC; Shahmanesh M; Boothby M; Nightingale P; Gathercole LL; Tripathi G; Harte AL; Shojaee-Moradie F; Umpleby AM; Das S; Al-Daghri NM; McTernan PG; Tomlinson JW
    Antivir Ther; 2012; 17(3):495-507. PubMed ID: 22300946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of adipose tissue composition on cardiovascular risk assessment in patients with stable coronary artery disease.
    Kunimura A; Ishii H; Uetani T; Harada K; Hirayama K; Harata S; Shibata Y; Kawashima K; Shimbo Y; Takayama Y; Tatami Y; Kawamiya T; Osugi N; Ota T; Yamamoto D; Okumura N; Suzuki S; Amano T; Murohara T
    Atherosclerosis; 2016 Aug; 251():206-212. PubMed ID: 27372206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
    Barrios A; Rendón A; Negredo E; Barreiro P; Garcia-Benayas T; Labarga P; Santos J; Domingo P; Sánchez-Conde M; Maida I; Martín-Carbonero L; Núñez M; Blanco F; Clotet B; Sambeat MA; Gil P; Gonzalez-Lahoz J; Cooper D; Soriano V
    AIDS; 2005 Mar; 19(6):569-75. PubMed ID: 15802975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of and Risk Factors for Low Bone Mineral Density Assessed by Quantitative Computed Tomography in People Living With HIV and Uninfected Controls.
    Thomsen MT; Wiegandt YL; Gelpi M; Knudsen AD; Fuchs A; Sigvardsen PE; Kühl JT; Nordestgaard B; Køber L; Lundgren J; Hansen AE; Kofoed KF; Jensen JB; Nielsen SD
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):165-172. PubMed ID: 31929404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study.
    Cotte L; Bénet T; Billioud C; Miailhes P; Scoazec JY; Ferry T; Brochier C; Boibieux A; Vanhems P; Chevallier M; Zoulim F
    J Hepatol; 2011 Mar; 54(3):489-96. PubMed ID: 21056493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.
    Karrer U; Ledergerber B; Furrer H; Elzi L; Battegay M; Cavassini M; Gayet-Ageron A; Hirschel B; Schmid P; Russotti M; Weber R; Speck RF;
    AIDS; 2005 Nov; 19(17):1987-94. PubMed ID: 16260905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brief Report: Prevalence of Peripheral Artery Disease Is Higher in Persons Living With HIV Compared With Uninfected Controls.
    Knudsen AD; Gelpi M; Afzal S; Ronit A; Roen A; Mocroft A; Lundgren J; Nordestgaard B; Sillesen H; Lebech AM; Køber L; Kofoed KF; Nielsen SD
    J Acquir Immune Defic Syndr; 2018 Nov; 79(3):381-385. PubMed ID: 29985264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
    J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
    Lowe SH; van Leeuwen E; Droste JA; van der Veen F; Reiss P; Lange JM; Burger DM; Repping S; Prins JM
    Ther Drug Monit; 2007 Oct; 29(5):566-70. PubMed ID: 17898645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine.
    Merchante N; Pérez-Camacho I; Mira JA; Rivero A; Macías J; Camacho A; Gómez-Mateos J; García-Lázaro M; Torre-Cisneros J; Pineda JA;
    Antivir Ther; 2010; 15(5):753-63. PubMed ID: 20710057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-related differences in abdominal fat distribution in premenopausal and postmenopausal women with cardiovascular disease.
    van der Leeuw J; Wassink AM; van der Graaf Y; Westerveld HE; Visseren FL;
    Menopause; 2013 Apr; 20(4):409-17. PubMed ID: 23168524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New dosing of ddI (Videx) and Nelfinavir (Viracept) approved.
    Highleyman L
    BETA; 1999; 12(4):3. PubMed ID: 11367246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with n-6 fatty acid content.
    Ebadi M; Baracos VE; Bathe OF; Robinson LE; Mazurak VC
    Clin Nutr; 2016 Dec; 35(6):1347-1353. PubMed ID: 26972089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abdominal Adiposity Distribution Quantified by Ultrasound Imaging and Incident Hypertension in a General Population.
    Seven E; Thuesen BH; Linneberg A; Jeppesen JL
    Hypertension; 2016 Nov; 68(5):1115-1122. PubMed ID: 27620395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.
    Japour AJ; Lertora JJ; Meehan PM; Erice A; Connor JD; Griffith BP; Clax PA; Holden-Wiltse J; Hussey S; Walesky M; Cooney E; Pollard R; Timpone J; McLaren C; Johanneson N; Wood K; Booth D; Bassiakos Y; Crumpacker CS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Nov; 13(3):235-46. PubMed ID: 8898668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of visceral and subcutaneous adipose tissue measurements and their ratio by magnetic resonance imaging in subjects with prediabetes, diabetes and healthy controls from a general population without cardiovascular disease.
    Storz C; Heber SD; Rospleszcz S; Machann J; Sellner S; Nikolaou K; Lorbeer R; Gatidis S; Elser S; Peters A; Schlett CL; Bamberg F
    Br J Radiol; 2018 Sep; 91(1089):20170808. PubMed ID: 29388794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of muscle toxicity with didanosine (ddI). Clinical and experimental studies.
    Pedrol E; Masanés F; Fernández-Solá J; Cofan M; Casademont J; Grau JM; Urbano-Márquez A
    J Neurol Sci; 1996 Jun; 138(1-2):42-8. PubMed ID: 8791237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.